ILIAS Biologics Revenue and Competitors
Estimated Revenue & Valuation
- ILIAS Biologics's estimated annual revenue is currently $4.2M per year.
- ILIAS Biologics's estimated revenue per employee is $155,000
Employee Data
- ILIAS Biologics has 27 Employees.
- ILIAS Biologics grew their employee count by -4% last year.
ILIAS Biologics's People
| Name | Title | Email/Phone |
|---|
ILIAS Biologics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is ILIAS Biologics?
At ILIAS Biologics, we dedicate ourselves to the development of paradigm-shifting advances in human medicine. Exosomes, extracellular vesicles naturally released by cells, represent such an opportunity thanks to its unique ability to deliver biological information between cells. Our platform technology, EXPLOR®, makes it possible to load large therapeutic molecules into exosomes, and we are actively developing various therapeutic exosomes, Exo-Targets®, as potential treatments for sepsis, pre-term birth, and various hard-to-treat diseases in inflammatory and metabolic areas. To learn more, please visit our website http://www.iliasbio.com or email us at BD@iliasbio.com
keywords:N/A
N/A
Total Funding
27
Number of Employees
$4.2M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ILIAS Biologics News
ILIAS Biologics Inc. Receives HREC Approval to Initiate First-in-Human Clinical Trial Evaluating Exosome Therapeutics ILB-202, the Treatment...
Other Companies in Yuseong-gu
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.2M | 27 | -7% | N/A |